ID-CMB305: Initiation of pivotal monotherapy trial in STS in H1 2018 (Immune Design) - Jun 17, 2017 - Corporate Presentation: 18-month survival data from P2 trial (NCT02609984) of CMB305 + atezolizumab in STS in H2 2018
New trial • P2 data • Oncology • Sarcoma
|